Loading patent…
AssigneesAgenus Inc., Memorial Sloan Kettering Cancer Center, Ludwig Institute for Cancer Research
InventorsVolker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
Estimating the term…
The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
An isolated antibody that specifically binds to human GITR, comprising a VH comprising the VH CDR1, VH CDR2, and VH CDR3 amino acid sequences and a VL comprising the VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of SEQ ID NOs:
An isolated antibody that specifically binds to human GITR comprising a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:
An isolated antibody that specifically binds to human GITR, wherein the antibody comprises a VH and a VL comprising the amino acid sequences of SEQ ID NOs:
Dependencies are inferred from the claim text.